Refinitiv Lipper Fund Awards Hong Kong 2023 - Best Fund Group - Overall⁷⁾ FOR HONG KONG INVESTORS ONLY

AsianInvestor Asset Management Awards 2022 - Fund House of the Year Awards -Hong Kong⁶)

SICAV Range

JPMorgan Funds - Global Healthcare Fund

- The Fund invests primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally.
- The Fund is therefore exposed to risks related to equity, concentration, Healthcare Companies, smaller companies, currency, derivative and hedging.
- Investors may be subject to substantial losses.
- Investors should not solely rely on this document to make any investment decision.

Fund overview

Investment objective

To achieve a return by investing primarily in pharmaceutical, biotechnology, healthcare services, medical technology and life sciences companies ("Healthcare Companies"), globally.

Expertise

Fund Manager Dom Valder, Bartjan van Hulten

Fund Information (A (acc) - USD)

	,e, eee)
Fund base currency USD	Denominated currency and NAV per unit
Total fund size (m)	A (acc) - USD : USD 506.60
USD 4,727.5	12 month NAV
SEDOL	High : USD 514.63 (26/02/24)
B558K58	Low : USD 417.30 (30/10/23)
ISIN code	
LU0432979614	
Bloomberg code	
JPHLUAA LX	
Current charge	
Initial : 5.0% of NAV	
Redemption : 0%	
Management fee : 1.5% p.a.	
Ratings	



2019 2020 2021 2022 2023 2024YTD A (acc) - USD3) 21.4 23.5 11.1 -9.3 2.7 5.5 Benchmark¹) 23.2 13 5 198 -54 38 5.0

Medalist Rating
Analyst-Driven %
Data Coverage %
Category

Bronze 10 99 Sector Equity Healthcare

Risk

1 2 3 4 5

1)Dividends reinvested after deduction of withholding tax. 2)This share class is not available on the J.P. Morgan eTrading platform. 3)Available for purchase in Hong Kong on 01.11.21. 4)With the exception of the "Average annual return" figure, all data are calculated from the month end after inception. 5)Investments in, or exposure to, any single entity (other than Government and other public securities) cannot exceed 10% of the Fund's total net asset value. 6)Issued by AsianInvestor, 2022 award reflecting performance as at the previous calendar year end. 7)Issued by Refinity Lipper, 2023 award reflecting performance as of 11.22022. Refinitiv Lipper (and Awards, predicating performance as of 11.22022. Refinitiv Lipper (and Awards, predicating performance as of 11.22022. Refinitiv Lipper (and Awards, predicating performance as of 11.22022. Refinitiv Lipper (and Awards, predicating benchmarked). Unless stated otherwise, all information as at the last valuation date of the previous content. Source: J.P. Morgan Asset Management/Factset (NAV to NAV to NAV in denominated currency with income reinvested). Risk ratings (if any) are based on J.P. Morgan Asset Management/Factset (NAV to NAV to nave reinvested). Any overweight in any investment holding exceeding the limit set out in the Investment Restrictions was due to market awards reflective of first governments and of reference only. Any overweight in any investment holding exceeding the limit set out in the Investment Restrictions was due to market the respective offering document(s).

Investment is used to react the respective of figure of courses in the second of the second of the respective of figure of courses in the second of the seco




Portfolio Analysis (A (acc) - USD)

	3 years	5 years	Since Launch4)
Correlation	0.90	0.93	0.92
Annualized Alpha %	-3.76	-1.31	0.02
Beta	0.92	0.99	1.08
Annualised volatility %	14.47	15.50	15.39
Sharpe ratio	0.03	0.39	0.72
Annualised tracking error %	6.45	5.69	6.22
Average annual return %	3.12	8.29	12.32

Holdings⁵⁾ (as at end February 2024)

TOP 10	Sector	%
Eli Lilly	Pharmaceutical	9.1
UnitedHealth	Healthcare Services	7.8
Novo Nordisk	Pharmaceutical	5.8
ABBVIE	Biotechnology	4.8
Regeneron Pharmaceuticals	Biotechnology	4.6
AstraZeneca	Pharmaceutical	4.3
Danaher	Medtech	3.7
Johnson & Johnson	Pharmaceutical	3.0
Centene	Healthcare Services	2.9
Stryker	Medtech	2.6

Portfolio Breakdown



Scan the QR code for fund documen



1)Dividends reinvested after deduction of withholding tax. 2)This share class is not available on the J.P. Morgan eTrading platform. 3)Available for purchase in Hong Kong on 01.11.21. 4)With the exception of the "Average annual return" figure, all data are calculated from the month end after inception. 5)Investments in, or exposure to, any single entity (other than Government and other public securities) cannot exceed 10% of the Fund's total net asset value. 6)Issued by AsianInvestor, 2022 award reflecting performance as at the previous calendar year end. 7)Issued by AsianInvestor, 2023 award reflecting performance as of 11.22.022. Refinity Lipper, 2023 award reflecting performance as of 31.12.2023. Refinity Lipper, 2023 award reflecting performance as of 31.12.2023. Refinity Lipper, 2023 award reflecting performance as of 31.22.023. Refinity Lipper, 2023 award reflecting performance as of 31.52.023. Refinity Lipper, 2023 award reflecting performance as of 31.52.023. Refinity Lipper, 2023 Refinity

Investment and win be required in the respective of future performance. Please refer to the offering document(s) for details, including the risk factors. This document has not been reviewed by the SFC. Issued by JPMorgan Funds (Asia) Limited. For more information, please contact your bank, financial adviser or visit am jpmorgan.com/hk today.

J.P.Morgan